Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors
Aura Moreno-Vega, Macarena Zambrano, Lilia Estrada-Virrueta, Xiangyu Meng, Julia Puig, Helene Neyret-Kahn, Mingjun Shi, Florent Dufour, Guerric Gilbert, Ke Li, Clarice Groeneveld, Jacqueline Fontugne, Mercedes Pérez-Escavy, Wajdi Dhifli, Clément Hua, Luc Cabel, Clémentine Krucker, Laura Tanguy, Sia Viborg Lindskrog, Claire Beraud, Yanina V. Langle, Tao Ye, Fariza Tahi, Irwin Davidson, Jesus M. Paramio, Lars Dyrskjøt, Yves Allory, Philippe Lluel, Ana Maria Eiján, Mohamed Elati, François Radvanyi, Catalina Lodillinsky, Isabelle Bernard-Pierrot
Aura Moreno-Vega, Macarena Zambrano, Lilia Estrada-Virrueta, Xiangyu Meng, Julia Puig, Helene Neyret-Kahn, Mingjun Shi, Florent Dufour, Guerric Gilbert, Ke Li, Clarice Groeneveld, Jacqueline Fontugne, Mercedes Pérez-Escavy, Wajdi Dhifli, Clément Hua, Luc Cabel, Clémentine Krucker, Laura Tanguy, Sia Viborg Lindskrog, Claire Beraud, Yanina V. Langle, Tao Ye, Fariza Tahi, Irwin Davidson, Jesus M. Paramio, Lars Dyrskjøt, Yves Allory, Philippe Lluel, Ana Maria Eiján, Mohamed Elati, François Radvanyi, Catalina Lodillinsky, Isabelle Bernard-Pierrot
View: Text | PDF
Research Article Genetics Oncology

FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors

  • Text
  • PDF
Abstract

Fibroblast growth factor receptor 3 (FGFR3) is one of the most frequently altered genes in bladder cancer, primarily through activating mutations that drive oncogenesis and are enriched in luminal tumors. However, the underlying gene regulatory network (GRN) remains poorly characterized. Here, we constructed an FGFR3-mutated GRN using a bottom-up bioinformatics approach, integrating transcriptomic data from bladder cancer cell lines, FGFR3-mutated tumors, and FGFR3 perturbation experiments in human and mouse models. Using publicly available CRISPR/Cas9 screening data, we identified transcription factors from this GRN that regulate the viability of FGFR3-mutated cells, with a focus on p63 (TP63). We showed that FGFR3 activation upregulates p63 in patient-derived xenografts and cell lines, while single-cell RNA sequencing revealed heterogeneous p63 activation associated with basal differentiation. Functional studies, including TP63 knockdown in FGFR3-dependent in vitro and in vivo models and RNA-seq along with p63 ChIP-seq, demonstrated that p63 directly promotes cell proliferation and migration and uncovered a positive feedback loop between FGFR3 and p63. Together, these findings support p63 as a protumorigenic regulator in FGFR3-mutated tumors despite their luminal differentiation and provide a detailed FGFR3-driven GRN, offering insights into FGFR3-induced oncogenic dependency and potential strategies to circumvent resistance to FGFR inhibitors.

Authors

Aura Moreno-Vega, Macarena Zambrano, Lilia Estrada-Virrueta, Xiangyu Meng, Julia Puig, Helene Neyret-Kahn, Mingjun Shi, Florent Dufour, Guerric Gilbert, Ke Li, Clarice Groeneveld, Jacqueline Fontugne, Mercedes Pérez-Escavy, Wajdi Dhifli, Clément Hua, Luc Cabel, Clémentine Krucker, Laura Tanguy, Sia Viborg Lindskrog, Claire Beraud, Yanina V. Langle, Tao Ye, Fariza Tahi, Irwin Davidson, Jesus M. Paramio, Lars Dyrskjøt, Yves Allory, Philippe Lluel, Ana Maria Eiján, Mohamed Elati, François Radvanyi, Catalina Lodillinsky, Isabelle Bernard-Pierrot

×

Figure 4

FGFR3 regulates p63 activity through ΔNp63 transcriptional regulation.

Options: View larger image (or click on image) Download as PowerPoint
FGFR3 regulates p63 activity through ΔNp63 transcriptional regulation.
(...
(A) Upstream regulator analysis using Ingenuity Pathway Analysis software (IPA) identifying p63 as inhibited following FGFR3 knockdown in FGFR3-dependent cell lines and activated in FGFR3-S249C–induced mouse bladder tumors. siFGFR3, FGFR3 siRNA; hFGFR3-S249C OE, human FGFR3-S249C overexpression. (B) ΔNp63 mRNA expression following FGFR3 inhibition in FGFR3-dependent bladder cancer cell lines (PD173074) for 48 hours (n = 3 independent experiments) (left) and in an FGFR3-S249C PDX (BGJ398, 30 mg/kg/d, 4 days) (n = 5 mice/group) (right). Statistical comparisons were performed using an unpaired 2-tailed t test. (C) Western blot analysis of p63 levels following siRNA-mediated FGFR3 knockdown (48 hours) or pharmacological inhibition in FGFR3-mutated cell lines (PD173074, 100 nM, 40 hours) (left) and PDX tumors (BGJ398, 30 mg/kg/d, 4 days) (right). (D) Time-course analysis of p63 protein expression following FGFR inhibition in RT112 cells (PD173074, 500 nM). (E) Spearman’s correlation between TP63 mRNA expression and FGFR3 pathway activity scores across UROMOL NMIBC and TCGA MIBC cohort, respectively. FGFR3 mutation status and molecular subtype for each individual tumor are indicated.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts